摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[3-(2-amino-6-oxo-1H-purin-9-yl)propanoylamino]benzoic acid

中文名称
——
中文别名
——
英文名称
4-[3-(2-amino-6-oxo-1H-purin-9-yl)propanoylamino]benzoic acid
英文别名
——
4-[3-(2-amino-6-oxo-1H-purin-9-yl)propanoylamino]benzoic acid化学式
CAS
——
化学式
C15H14N6O4
mdl
——
分子量
342.31
InChiKey
AKUDYIOEMKDMHQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    152
  • 氢给体数:
    4
  • 氢受体数:
    5

文献信息

  • Methods for treatment of disease-induced peripheral neuropathy and related conditions
    申请人:Spectrum Pharmaceuticals, Inc.
    公开号:EP1790344A2
    公开(公告)日:2007-05-30
    The use of a compound of formula (I) in the manufacture of a medicament for the treatment of peripheral neuropathy. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting.
    将式(I)化合物用于制造治疗周围神经病变的药物。该化合物可通过神经生长因子(NGF)等神经营养因子的作用诱导周围神经萌发,而不会出现痛觉减退。外周神经萌发可以是痛觉神经萌发。
  • Methods for stimulation of synthesis of synaptophysin in the central nervous system
    申请人:——
    公开号:US20020040032A1
    公开(公告)日:2002-04-04
    A method of increasing the synthesis and/or secretion of synaptophysin comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.
    一种增加突触素合成和/或分泌的方法包括向神经系统疾病患者或有患神经系统疾病风险的患者施用有效量的嘌呤衍生物或类似物、四氢吲哚酮衍生物或类似物或嘧啶衍生物或类似物。如果化合物是嘌呤衍生物,嘌呤分子可以是鸟嘌呤或次黄嘌呤。神经系统疾病可以是神经退行性疾病,如阿尔茨海默病,也可以是神经发育障碍,如唐氏综合征。通常情况下,化合物可以通过血脑屏障。嘌呤分子可以是次黄嘌呤或鸟嘌呤。一种特别优选的嘌呤衍生物是 N-4-羧基苯基-3-(6-氧代氢嘌呤-9-基)丙酰胺。
  • Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
    申请人:——
    公开号:US20020040031A1
    公开(公告)日:2002-04-04
    A method of either inhibiting the formation of A&bgr; or stimulating the formation of sAPP comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.
    一种抑制 A&bgr 形成或刺激 sAPP 形成的方法包括向神经系统疾病患者或有患神经系统疾病风险的患者施用有效量的嘌呤衍生物或类似物、四氢吲哚酮衍生物或类似物或嘧啶衍生物或类似物。如果化合物是嘌呤衍生物,嘌呤分子可以是鸟嘌呤或次黄嘌呤。神经系统疾病可以是神经退行性疾病,如阿尔茨海默病,也可以是神经发育障碍,如唐氏综合征。通常情况下,化合物可以通过血脑屏障。嘌呤分子可以是次黄嘌呤或鸟嘌呤。一种特别优选的嘌呤衍生物是 N-4-羧基苯基-3-(6-氧代氢嘌呤-9-基)丙酰胺。
  • Methods for treatment of drug-induced peripheral neuropathy and related conditions
    申请人:——
    公开号:US20020061899A1
    公开(公告)日:2002-05-23
    A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. Methods according to the present invention are particularly useful in treating peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.
    一种治疗药物性周围神经病变的方法包括向药物性周围神经病变患者施用有效量的嘌呤衍生物或类似物、四氢吲哚酮衍生物或类似物或嘧啶衍生物或类似物。如果化合物是嘌呤衍生物,嘌呤分子可以是鸟嘌呤或次黄嘌呤。该化合物可通过神经生长因子(NGF)等神经营养因子的作用诱导外周神经萌发,而不会出现痛觉减退。外周神经萌发可以是痛觉神经萌发。药物诱导的周围神经病变可以是与服用溶瘤药物相关的药物诱导的周围神经病变,如长春花生物碱、顺铂、紫杉醇、苏拉明、阿曲他胺、卡铂、氯霉素、阿糖胞苷、达卡巴嗪、多西他赛、依托泊苷、氟达拉滨、伊福法胺与美司那、他莫昔芬、替尼泊苷或硫鸟嘌呤。根据本发明的方法尤其适用于治疗与长春新碱、紫杉醇或顺铂用药相关的周围神经病变。
  • Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
    申请人:Eve M. Taylor
    公开号:US20020091133A1
    公开(公告)日:2002-07-11
    The present invention is directed to a method of inducing neurogenesis by administering to a mammal an effective quantity of a compound that induces neurogenesis, where neurogenesis includes proliferation of neural stem and progenitor cells, differentiation of these cells into neurons, and/or survival of these new neurons. In general, the compound comprises three moieties, A, L, and B, covalently linked. A can be a purine, tetrahydroindolone, or pyrimidine; L is a linker, while B is a moiety that promotes absorption of the compound. A particularly preferred compound is N4-[[3-(6-oxo-1,6-dihydropurin-9-yl)-1-oxopropyl] amino] benzoic acid (also known as AIT-082 or leteprinim potassium). Another aspect of the invention is pharmaceutical compositions for inducing neurogenesis.
    本发明涉及一种诱导神经发生的方法,通过向哺乳动物施用有效量的诱导神经发生的化合物,其中神经发生包括神经干细胞和祖细胞的增殖、这些细胞分化成神经元和/或这些新神经元的存活。一般来说,化合物由共价连接的三个分子 A、L 和 B 组成。A 可以是嘌呤、四氢吲哚酮或嘧啶;L 是连接剂,而 B 是促进化合物吸收的分子。一种特别优选的化合物是 N4-[[3-(6-氧代-1,6-二氢嘌呤-9-基)-1-氧代丙基]氨基]苯甲酸(又称 AIT-082 或来替普林钾)。本发明的另一方面是用于诱导神经发生的药物组合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐